A. Lokare

发表

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

G. Lyman, F. Hobbs, A. Maraveyas, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of venous thromboembolism in patients experiencing direct oral anticoagulant treatment failure: a single-center review of practice and outcomes

N. Smith, G. McIlroy, A. Lokare, 2020, Journal of Thrombosis and Thrombolysis.

Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism : results of the 'select-d' Pilot Trial

A. Marshall, J. Dunn, M. Levine, 2018 .

Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial

A. Marshall, J. Dunn, M. Levine, 2017 .

Diagnosis, management, and outcomes of venous thromboembolism in COVID-19 positive patients: a role for direct anticoagulants?

H. Osman, A. Lokare, C. Kartsios, 2020, Journal of Thrombosis and Thrombolysis.

Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)

F. Hobbs, A. Maraveyas, A. Marshall, 2020, Journal of thrombosis and haemostasis : JTH.

Impact of venous thromboembolism on survival in patients with malignancy

T. Nokes, P. Rose, R. Arya, 2009, British journal of haematology.

Reduced Intensity Allogeneic Stem Cell Transplant for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Z. Rudzki, D. Milligan, S. Paneesha, 2014, Hematology reports.

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

M. Drayson, E. Low, J. Dunn, 2019, The Lancet. Oncology.

OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.

A. Marshall, J. Dunn, A. Young, 2016, Thrombosis research.

Thrombocytopenia as an initial manifestation of COVID‐19; case series and literature review

J. Ewing, A. Lokare, H. Giles, 2020, British journal of haematology.

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

R. Houlston, M. Drayson, M. Jenner, 2022, Blood.

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

R. Houlston, M. Drayson, M. Jenner, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial

M. Drayson, M. Jenner, G. Cook, 2021, Clinical Lymphoma Myeloma and Leukemia.

Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019

Quentin M. Hill, R. Buka, G. Benson, 2022, Journal of thrombosis and haemostasis : JTH.

Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients

N. Smith, G. McIlroy, A. Lokare, 2018, Blood.

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

G. Lyman, F. Hobbs, A. Maraveyas, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.